Enumeral Biomedical Holdings is Drug Discovery in United States that focus on developer business. Founded in 2009. They cover business area such as developer, novel antibody immunotherapy, immune system attack diseased cell, enable physician, new drug, cancer, infectious and inflammatory disease, order, patient, diagnosis, treatment, infectious, autoimmune and inflammatory disease.
2009
( 15 years old in 2024 )
Developer
-
1337 Massachusetts Avenue
Suite 243
Arlington, MA 02476
United States
Private
developernovel antibody immunotherapyimmune system attack diseased cellenable physiciannew drugcancerinfectious and inflammatory diseaseorderpatientdiagnosistreatmentinfectious, autoimmune and inflammatory disease
* We use standard office opening hours in near Enumeral Biomedical Holdings's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Enumeral Biomedical Holdings is Drug Discovery business from United States that founded in 2009 (15 years old in 2024), Enumeral Biomedical Holdings business is focusing on Developer.
Enumeral Biomedical Holdings headquarter office and corporate office address is located in 1337 Massachusetts Avenue Suite 243 Arlington, MA 02476 United States.
Enumeral Biomedical Holdings was founded in United States.
In 2024, Enumeral Biomedical Holdings is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Enumeral Biomedical Holdings, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
